Previous studies have proved that the TGF-β/Smad4 pathway is an action target of many potential antitumor drugs, such as acetylsalicylic acid in breast cancer [41], baicalein in gastric cancer [42], and Hedyotis diffusa willd in colorectal cancer [43]. This evidence concerns the gene TGFB1 and breast cancer.